Unresectable Melanoma (DBCOND0047213)

Identifiers

Synonyms

Melanoma Unresectable

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Binimetinib	A medication used to treat metastatic melanoma with specific mutations.	UDP-glucuronosyltransferase 1A1enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Dual specificity mitogen-activated protein kinase kinase 2target Albumincarrier Dual specificity mitogen-activated protein kinase kinase 1target Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter
Cobimetinib	An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.	Dual specificity mitogen-activated protein kinase kinase 1target Cytochrome P450 3A4enzyme Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter UDP-glucuronosyltransferase 2B7enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A5enzyme Alpha-1-acid glycoprotein 1carrier
Dabrafenib	A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.	Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Serine/threonine-protein kinase B-raftarget RAF proto-oncogene serine/threonine-protein kinasetarget Serine/threonine-protein kinase SIK1target Serine/threonine-protein kinase Nek11target LIM domain kinase 1target Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 1A2enzyme Albumincarrier Solute carrier organic anion transporter family member 1A2transporter Solute carrier family 22 member 2transporter UDP-glucuronosyltransferase 1A1enzyme
Encorafenib	A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations.	Cytochrome P450 3A4enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme Serine/threonine-protein kinase B-raftarget G1/S-specific cyclin-D1target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter RAF proto-oncogene serine/threonine-protein kinasetarget Mitogen-activated protein kinase 8target Mitogen-activated protein kinase 9target Mitogen-activated protein kinase 10target LIM domain kinase 1target LIM domain kinase 2target Dual specificity mitogen-activated protein kinase kinase 4target Serine/threonine-protein kinase 36target
Ipilimumab	A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.	Cytotoxic T-lymphocyte protein 4target
Lifileucel	An autologous T cell immunotherapy used to treat unresectable or metastatic melanoma in previously treated adults.	No drug targets
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Relatlimab	A monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma.	Lymphocyte activation gene 3 proteintarget
Trametinib	A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.	Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Dual specificity mitogen-activated protein kinase kinase 1target Dual specificity mitogen-activated protein kinase kinase 2target
Vemurafenib	A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation.	Albumincarrier Alpha-1-acid glycoprotein 1carrier Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A4enzyme Serine/threonine-protein kinase B-raftarget Multidrug resistance-associated protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05732805	A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma	Nurulimab Prolgolimab	treatment	3	recruiting
NCT04698187	CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma	Nivolumab Vidutolimod	treatment	2	completed
NCT04695977	CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma	Nivolumab Vidutolimod	treatment	2 / 3	completed
NCT06151847	Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	Cyclophosphamide Fludarabine Human interleukin-2 Lifileucel Teceleukin	treatment	2	recruiting
NCT03430297	A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma	Dacarbazine Toripalimab	treatment	3	active_not_recruiting
NCT05303493	Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma	No drug interventions	treatment	1	recruiting
NCT05428007	Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma	Ipilimumab Nivolumab Relatlimab Sarilumab	treatment	2	recruiting
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	Dabrafenib Navitoclax Trametinib	treatment	1 / 2	active_not_recruiting
NCT03816332	Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	Cortisone Ipilimumab Nivolumab Prednisone Tacrolimus	treatment	1	active_not_recruiting
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Ipilimumab Nivolumab Tocilizumab	treatment	2	active_not_recruiting
NCT04526899	Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	BNT111 Cemiplimab	treatment	2	active_not_recruiting
NCT04462406	Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	Ipilimumab Nivolumab Pembrolizumab	treatment	2	recruiting
NCT06199713	Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients	No drug interventions	Not Available	Not Available	recruiting
NCT04688658	Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma	Axitinib Duvelisib Nivolumab	treatment	1 / 2	active_not_recruiting
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT02650986	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1	Cyclophosphamide Decitabine Lifileucel	treatment	1 / 2	active_not_recruiting
NCT01738139	Ipilimumab and Imatinib Mesylate in Advanced Cancer	Imatinib Ipilimumab	treatment	1	completed
NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Dabrafenib Methane Trametinib Uprosertib	treatment	1 / 2	active_not_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT03679767	A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	Retifanlimab	treatment	2	completed
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Dabrafenib Ipilimumab Methane Nivolumab Trametinib	treatment	3	active_not_recruiting
NCT02419495	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	Calcium Camptothecin Capecitabine Carboplatin Cyclophosphamide Daunorubicin Doxorubicin Eribulin Escitalopram Fluorouracil Ipilimumab Irinotecan Leucovorin Levoleucovorin Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	treatment	1	active_not_recruiting
NCT05764395	Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors	Pembrolizumab Rigosertib	treatment	2	recruiting
NCT01134614	Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	Ipilimumab Sargramostim	treatment	2	active_not_recruiting
NCT02115243	Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma	Ipilimumab	treatment	1	completed
NCT04493203	Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma	Axitinib Nivolumab	treatment	2	active_not_recruiting
NCT05155254	IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Pembrolizumab	treatment	3	active_not_recruiting
NCT04625205	NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma	No drug interventions	treatment	1	recruiting
NCT05628883	Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Cyclophosphamide Fludarabine Human interleukin-2	treatment	1	recruiting
NCT05653661	Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors	Danburstotug Paclitaxel	treatment	1	recruiting
NCT02020707	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	Albumin human Albumin-stabilized nanoparticle (130 nm) Bevacizumab Paclitaxel	treatment	1	completed
NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	Binimetinib Dabrafenib Encorafenib Nivolumab Trametinib	treatment	2	active_not_recruiting
NCT04521075	A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	Nivolumab	treatment	1 / 2	unknown_status
NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	Dabrafenib Hydroxychloroquine Trametinib	treatment	2	terminated
NCT01927419	Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma	Ipilimumab Nivolumab	treatment	2	completed
NCT06466434	Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma	No drug interventions	supportive_care	2	not_yet_recruiting
NCT02965716	Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	Pembrolizumab Talimogene laherparepvec	treatment	2	active_not_recruiting
NCT04967196	Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT05896839	Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	Cortisone Ipilimumab Nivolumab Prednisone Sirolimus	treatment	1 / 2	recruiting
NCT04616248	In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors	CDX-301 Carboxymethylcellulose Hiltonol Lysine Polyinosinic-polycytidylic acid	treatment	1	recruiting
NCT04703426	Sargramostim (GM-CSF) + PD-1	Pembrolizumab Sargramostim	treatment	2	withdrawn
NCT02595866	Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	Pembrolizumab	treatment	1	completed
NCT01107665	Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma	Paclitaxel Pazopanib	treatment	2	completed
NCT05361174	A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer	No drug interventions	treatment	1 / 2	recruiting
NCT02158520	Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	Albumin human Bevacizumab Ipilimumab Paclitaxel	treatment	2	completed
NCT04337931	A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma	Sotigalimab	treatment	2	terminated
NCT03719131	Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy	Hyaluronidase (human recombinant) Ipilimumab Nivolumab Rituximab	treatment	2	active_not_recruiting
NCT03033576	Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT03021460	Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery	No drug interventions	treatment	1	active_not_recruiting
NCT05103891	Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations	Binimetinib	other	1	unknown_status
NCT04645680	Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study	No drug interventions	supportive_care	2	active_not_recruiting
NCT05717140	Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	Nivolumab Sargramostim	treatment	1	not_yet_recruiting
NCT05398640	Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma	Lifileucel	Not Available	Not Available	no_longer_available
NCT05810740	Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations	Binimetinib	other	1	completed
NCT05727904	Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.	Lifileucel Pembrolizumab	treatment	3	recruiting
NCT03501368	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	Ceritinib Trametinib	treatment	1	active_not_recruiting
NCT04759846	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	Binimetinib Encorafenib	treatment	1	withdrawn
NCT03865212	Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma	Human interferon beta Tyrosinase	treatment	1	active_not_recruiting
NCT02196181	Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery	Dabrafenib Methane Trametinib	treatment	2	active_not_recruiting
NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	Dabrafenib Trametinib	treatment	2	completed
NCT01950390	Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	Bevacizumab Ipilimumab	treatment	2	active_not_recruiting